Tegaserod is a 5-HT₄ agonist used for the management of constipation-predominant irritable bowel syndrome (IBS). It is currently marketed by Novartis under the trade names Zelnorm (in the US) or Zelmac (in other countries).

Tegaserod is a motility stimulant. Therapeutic effect is achieved through activation of 5-HT₄ receptors of the enteric nervous system in the gastrointestinal tract. Tegaserod stimulates gastrointestinal motility and the peristaltic reflex, and possibly also reduces abdominal pain (Rossi, 2004).

References

• Rossi, S (Ed.) (2004). Australian Medicines Handbook 2004 (AMH). Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2.

External links

• Zelnorm (manufacturer's website)
• Tegaserod (patient information)

Motility stimulants